BioLife Solutions: Powering the Preservation Sciences

BioLife Solutions has a strong interest in target markets: regenerative medicine, biobanking, and drug discovery. The company serves a market of over $500 million and under 2013 guidance, the company aims to have a revenue growth of $6.5-7 million. The company highlights biopreservation by creating products that enable 2x to 3x longer shelf-life of cell and tissue-based clinical therapies and in addition, the company aims to increase the yield and viability of cells in the clinical dose.

The realms of the company’s intellectual property includes 5 issued patents, several submitted applications, and about 300 third party issued and pending patents citing use of BioLife products. The embedded technology of the company has critical supplier status with leading companies, including regenerative medicine, cord blood banks, and suppliers of cells used in drug screening. The company projects the regenerative medicine market growth to be from $1.4 billion in 2012 to $10 billion in 2020 and the demand of biopreservation media to increase from $150 million in 2011 to $500 million by 2018.
To learn more about BioLife Solutions, Inc be sure to see them at the 7th Annual OneMedForum in San Francisco from January 13th-15th.

The comments are closed.